Trials / Completed
CompletedNCT05238597
A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease
A Phase 2, Multicenter, Double-Masked, Randomized, Vehicle-Controlled Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 207 (actual)
- Sponsor
- Aramis Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this trial are to assess the safety, tolerability and efficacy of A197 ophthalmic solution in comparison to a vehicle control in the treatment of subjects with Dry Eye Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | A197 Ophthalmic Solution | A197 Ophthalmic Solution |
| DRUG | A197 Vehicle Control | A197 Vehicle Control |
| DRUG | Active Comparator | Active Comparator |
Timeline
- Start date
- 2022-01-25
- Primary completion
- 2023-01-24
- Completion
- 2023-01-24
- First posted
- 2022-02-14
- Last updated
- 2023-05-16
Locations
24 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05238597. Inclusion in this directory is not an endorsement.